Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma

Clinical Therapeutics

Volumn 22, Issue 12, 2000, Pages 1502-1515

  Einarson, Thomas R ^a,b   Kulin, Nathalie A ^b   Tingey, David ^c,d   Iskedjian, Michael ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PharmIdeas Research and Consulting Inc   (Canada)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Brimonidine; Clinical trials; Intraocular pressure; Latanoprost; Meta analysis

Indexed keywords

BETAXOLOL; BRIMONIDINE; LATANOPROST; PLACEBO; TIMOLOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OPEN ANGLE GLAUCOMA; TONOMETRY;

EID: 0034528085     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)83048-9     Document Type: Article

References (49)

1. Treatment of glaucoma
2. Why do some people go blind from glaucoma?
3. Screening for glaucoma. Why is the disease underdetected?
4. Prevalence of glaucoma in Ponza, Italy: A comparison with other studies
5. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study
6. The age distribution of primary open angle glaucoma
7. Prevalence of glaucoma and distribution of intraocular pressure in a population. The Casteldaccia Eye Study
8. Glaucoma risk factors observed in the Baltimore Eye Survey
9. Adverse effects of local use of beta-blockaders in glaucoma. A literature review and a survey of reports to the adverse drug reaction authority 1986-95
10. Comparison of the ocular beta-blockers
11. Long-term effect of ophthalmic beta-adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma
12. Relationship between intraocular pressure and visual field progress in chronic simple glaucoma and ocular hypertension
13. The Ocular Hypertension Treatment Study: Design and baseline description of the participants
14. Longterm visual field follow-up of glaucoma patients treated with betablockers
15. Betaxolol
16. The role of brimonidine in the treatment of open-angle glaucoma
17. Betaxolol eye drops. A clinical trial of safety and efficacy
18. Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension
19. Pharmacological advances in the treatment of glaucoma
20. Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group
21. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups
22. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group
23. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group
24. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension
25. Corneal toxicity associated with latanoprost
26. Latanoprost and herpes simplex keratitis
27. 2-adrenoreceptor agonist for glaucoma treatment
28. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension
29. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension
30. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III
31. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group
32. Ocular betablockers in glaucoma management. Clinical pharmacological aspects
33. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
34. A method for meta-analysis of epidemiological studies
35. The combination of estimates from different experiments
36. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example
37. Integrating findings: The meta-analysis of research
38. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma
39. The effect of latanoprost vs timolol on intraocular pressure in patients with glaucoma and ocular hypertension
40. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group
41. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study
42. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group
43. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2
44. Rules of evidence and clinical recommendations on the use of antithrombotic agents
45. Cost considerations of medical therapy for glaucoma
46. Xalatan® product monograph
47. Alphagan® product monograph